PRAX

Praxis Precision MedicinesC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$410.00

+47.0% vs current

Most likely

Base case

45%

Probability

Target price

$225.00

-19.3% vs current

B-

Bear case

35%

Probability

Target price

$115.00

-58.8% vs current

AI sentiment snapshot

Latest data as of 2026-06-03

AI commentary

Primary-source June 1 8-K confirms the negative read: POWER1 missed its primary success measure and POWER2 enrollment was paused for reassessment [#SEC-8K-2026-06-01]. The May 7 10-Q still shows a strong balance sheet (~$1.4bn cash, cash equivalents and marketable securities) with Q1 operating cash use of $86.2m [#SEC-10Q-2026-05-07], so this is more an execution/valuation reset than an immediate liquidity problem. Secondary coverage points to an abrupt post-news selloff, but there is no visible analyst-revision signal in the packet yet, so the setup is negative and still unfolding.

RankAlpha Sentiment Codex - 2026-06-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-05catalystImmediate de-risking after POWER1 missHigh impact

The June 1 8-K says the Phase 2/3 POWER1 study in highly refractory focal onset seizures did not meet its primary success measure and management paused POWER2 enrollment to reassess vormatrigine, so near-term selling pressure can persist while investors digest the setback [#SEC-8K-2026-06-01].

2026-09-30eventVormatrigine program reset becomes the next hard catalystHigh impact

Because the company is pausing POWER2 to determine potential modifications, the next disclosure on whether vormatrigine is redesigned, delayed, or narrowed will be the key read-through for the focal-onset seizure franchise [#SEC-8K-2026-06-01].

2027-03-31catalystCash runway keeps the rest of the pipeline fundedHigh impact

The March 31, 2026 10-Q shows about $1.4 billion of cash, cash equivalents and marketable securities and Q1 operating cash use of $86.2 million, which gives PRAX time to absorb the vormatrigine setback without an immediate financing overhang [#SEC-10Q-2026-05-07].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-03 • Updated nightlySource: Internal modelMethodology